

Supplementary Table 1: Prescribing guidelines for medications examined in the study.

A. Prescribing guidelines for all medications examined in the study (according to the French SPCs, as assessed from January 2017 to March 2017) B. Prescribing guidelines for antidiabetic agents examined in the study (according to the ERBP 2015 recommendations^a) C. Prescribing guidelines for antidiabetic agents examined in the study (according to the KDOQI 2012 recommendations^b).

A. Prescribing guidelines for all medications examined in the study (according to the French SPCs, as assessed from January 2017 to March 2017).

Drugs	Creatinine clearance rate, mL/min	Maximum recommended dose level, mg
ANTIHYPERTENSIVES		
Methyldopa	<60	3000
Clonidine	<60	0.60
Moxonidine	30-60	0.4
	15-30	0.3
Rilmenidine	<15	CI
Hydrochlorothiazide	<30	CI
Indapamide	<30	CI
Cicletanine	30-60	100
	<30	CI
Piretanide	<20	CI
Spironolactone	<30	CI
Eplerenone	<30	CI
Sotalol	30-60	160
	10-30	80
	<10	CI
Nadolol	30-50	80
	<30	40
Tertatolol	10	CI
Atenolol	15-35	50
	<15	25
Acebutolol	25-50	400
	<25	200
Betaxolol	<20	20
Bisoprolol	<60	10
Celiprolol	<15	NR
Manidipine	<10	CI
Lercanidipine	<10	CI
Diltiazem	<60	180
Captopril	21-40	100
	11-20	75
	<10	37.5
Enalapril	<60	40
Lisinopril	<80	40
Perindopril	30-60	2.5
	<30	1.25
Ramipril	<60	5
Quinapril	<60	40
Benazepril	<30	5
Trandolapril	11-30	1
	<10	0.5
Zofenopril	<45	15
Olmesartan medoxomil	20-60	20
	<20	NR
Aliskiren	<30	NR

LIPID-MODIFYING AGENTS		
Rosuvastatin	30-60	35
	<30	CI
Bezafibrate	<60	CI
Gemfibrozil	<30	CI
Fenofibrate	<30	CI
Ciprofibrate	<60	CI
ANTITHROMBOTIC AGENTS		
Enoxaparin	<30	CI
Nadroparin	<30	CI
Tinzaparin	<30	CI
Fondaparinux	<30	CI
Warfarin	<20	NR
Acenocoumarol	<20	NR
Fluindione	<20	NR
Dabigatran etexilate	30-50	220
	<30	CI
Rivaroxaban	15-50	15
	<15	NR
Apixaban	15-30	5
	<15	NR
DRUGS USED IN DIABETES		
Metformin	45-60	2000
	30-45	1000
	<30	CI
Glibenclamide	<30	CI
Glipizide	<30	CI
Gliclazide	<30	CI
Glimepiride	<30	CI
Acarbose	<25	CI
Miglitol	<25	CI
Sitagliptin	30-50	50
	<30	25
Vildagliptin	<50	50
Saxagliptin	60	2.5
	<15	NR
Exenatide	<30	NR
Liraglutide	<30	NR
DRUGS FOR ACID-RELATED DISORDERS		
Salt associations (ex: Maalox®)	<30	CI
Antacids (ex: Carbosymag®, Gelox®)	<30	CI
Ranitidine	<50	150
Metoclopramide	<15	7.5
Domperidone	<30	20
Mesalazine	<30	CI
ANTIGOUT PREPARATIONS		
Allopurinol	80-100	300
	40-80	200
	20-40	100
	<20	50
Probenecid	<60	CI
Colchicine	30-60	2
	<30	CI
ANALGESICS		

Dihydrocodeine	30-60	120
	<30	CI
Tramadol	10-60	400
	<10	NR
Tramadol (Sustained release formulations)	30-60	200
	<30	NR
Acetylsalicylic acid	<30	CI
Paracetamol	<30	3000
Naratriptan	30-80	2.5
	<30	CI
Zolmitriptan	<15	CI
Rizatriptan	30-80	10
	30	CI
Eletriptan	<30	CI
PSYCHOLEPTICS		
Clozapine	<30	CI
Amisulpride	30-60	600
	10-30	400
Risperidone	<60	3
Diazepam	<60	20
Oxazepam	<60	75
Clorazepate potassium	<60	45
Lorazepam	<60	3.75
Bromazepam	<60	18
Clobazam	<60	30
Prazepam	<60	15
Alprazolam	<60	0.5
Nordazepam	<60	7.5
Clotiazepam	<60	15
Hydroxyzine	<60	150
Buspirone	<30	CI
Etifoxine	<30	CI
Lormetazepam	<60	1
Loprazolam	<60	0.5
MINERAL SUPPLEMENTS		
Potassium chloride	<60	CI
Potassium citrate	<60	CI
Potassium carbonate acid	<60	CI
Magnesium aspartate	<30	CI
Magnesium lactate	<30	CI
Magnesium pidolate	<30	CI
Magnesium oxyde	<30	CI
Other mineral elements (Ex: Phosphoneuros®)	<60	CI
CARDIAC THERAPY		
Digoxin	<30	0.0625
Disopyramide	31-60	250
	<30	200
Flecainide	<20	100
Cibenzoline	20-40	3MG/KG/D
	10-20	2.5MG/KG/D
Midodrine	<30	CI
Trimetazidine	30-60	40
	<30	CI
UROLOGICALS		
Solifenacine	<30	5

Trospium	10-30	20
Yohimbine	<30	CI
Tadalafil	<30	10
Vardenafil	<15	CI
Alfuzosine	<30	CI
Sildenafil	<30	NR
PSYCHOANALEPTICS		
Imipramine	<60	150
Clomipramine	<60	250
Trimipramine	<60	150
Amitriptyline	<60	150
Citalopram	<20	CI
Paroxetine	<60	20
Tianeptine	<60	25
Venlafaxine	<30	187.5
Milnacipran	60-80	100
	30-60	50
	10-30	25
Duloxetine	<30	CI
Piracetam	<60	2400
Galantamine	<9	CI
Memantine	30-49	20
	6-29	10
ANTIEPILEPTICS		
Phenobarbital	<60	3 MG/KG/D
Primidone	<60	1500
Clonazepam	<60	0.05 MG/KG/D
Valproic acid	<60	30 MG/KG/D
Topiramate	<70	250
Gabapentin	50-80	1800
	30-49	900
	15-29	600
	<15	300
Levetiracetam	50-80	2000
	30-49	1500
	<30	1000
Pregabalin	60-80	600
	30-60	300
	<15	75
ANTIBACTERIALS FOR SYSTEMIC USE		
Amoxicillin	10-30	1000
	<10	500
Cloxacillin	30	2000
Cephalexin	30-60	1000
	6-30	500
	<5	250
Cefotiam	<20	CI
Cefixime	<20	200
Cefpodoxime	<40	200
Clarithromycin	<30	500
Telithromycin	<30	NR
Ofloxacin	20-60	200
	<20	100
Ciprofloxacin	30-60	1000
	<30	500
Levofloxacin	50-60	1000

	20-50	500
	10-20	250
	<10	125
Nitrofurantoin	<45	CI
IMMUNOSUPPRESSANTS		
Mycophenolic acid	<25	2000
Leflunomide	<60	CI
Anakinra	<30	CI
Azathioprine	<80	150
Lenalidomide	30-60	10
	<30	7.5
Methotrexate	<30	CI
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS		
Diclofenac	<30	CI
Piroxicam	<30	CI
Meloxicam	<30	CI
Ibuprofen	<30	CI
Naproxen	<30	CI
Ketoprofen	30-60	200
	<30	CI
Flurbiprofen	<30	CI
Tiaprofenic acid	<30	CI
Diacerein	<30	50
BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS		
Electrolytes solution for perfusion (Ex: Ionoven®)	<30	CI
Magnesium sulfate	<30	CI
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM		
Danazol	<30	CI
Raloxifene	<30	CI
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES		
Desmopressin	<50	CI
ANTIMYCOTICS FOR SYSTEMIC USE		
Fluconazole	<50	200
ANTIMYCOBACTERIALS		
Rifampicin	<30	600
Rifabutin	<60	CI
Isoniazid	<30	300
Ethambutol	70-100	15MG/KG/D
	<70	10MG/KG/D
ANTIVIRALS FOR SYSTEMIC USE		
Aciclovir	>50	800
	25-50	600
	10-25	400
	<10	200
Ribavirin	30-50	400
	<30	200
Valaciclovir	≥50	3000
	30-49	200
	10-29	1000
	<10	500
Valganciclovir	≥60	900
	40-59	450
	25-39	450/2D

	10-24	900/WEEK
	<10	NR
Lamivudine	30-50	50
	15-30	25
	6-15	15
	<5	10
	<15	NR
Abacavir	<15	NR
Tenofovir disoproxil	50-80	245/D
	30-50	857.5/WEEK
	20-30	490/WEEK
	10-20	245/WEEK
Emtricitabine	≥30	200
	15-30	200/72H
	<15	200/96H
Entecavir	≥50	1
	30-50	0.5
	10-30	0.3
	<10	0.1
ANTINEOPLASTIC AGENTS		
Carboplatin	<20	CI
Hydroxycarbamide	<60	30MG/KG/D
IMMUNOSTIMULANTS		
Peg interferon alfa-2b	<30	CI
DERMATOLOGICALS		
Terbinafine	<30	CI
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN		
Ketoprofen (topicals)	<60	NR
Ibuprofen (topicals)	<30	CI
MUSCLE RELAXANTS		
Baclofen	<60	80
DRUGS FOR TREATMENT OF BONE DISEASES		
Alendronic acid	<35	NR
Risedronic acid	<30	CI
Zoledronic acid	<35	CI
Strontium ranelate	<30	NR
ANTI-PARKINSON DRUGS		
Ropinirole	<30	CI
Pramipexole	20-50	1.57
	<20	1.1
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES		
Bambuterol	<60	10
ANTIHISTAMINES FOR SYSTEMIC USE		
Doxylamine	<60	30
Cetirizine	50-80	10
	30-49	5
	10-30	5 /2D
	<10	CI
Levocetirizine	50-79	5
	30-49	5/2D
	10-30	5/3D
	<10	CI
Rupatadine	<60	NR

OPHTHALMOLOGICALS		
Dorzolamide	<30	CI
Brinzolamide	<30	CI
ALL OTHER THERAPEUTIC PRODUCTS		
Magnesium (Magne B6®, Mag2®, Sympathyl®)	<30	CI
Hydroxychloroquine	<60	400

B. Prescribing guidelines for antidiabetic agents examined in the study (according to the KDOQI 2012 recommendations^a).

Drugs	Creatinine clearance rate, ml/min/1.73m²	Maximum recommended dose level, mg/day
DRUGS USED IN DIABETES		
Metformin	45-60	2000
	30-45	1000
	<30	CI
Glibenclamide	<60	CI
Acarbose	<30	CI
Miglitol	<25	CI
Sitagliptin	30-50	50
	<30	25
Vildagliptin	<50	50
Saxagliptin	≤50	2.5
Exenatide	<30	NR
Liraglutide	<60	NR

C. Prescribing guidelines for antidiabetic agents examined in the study (according to the ERBP 2015 recommendations^b).

Drugs	Creatinine clearance rate, ml/min/1.73m²	Maximum recommended dose level, mg/day
DRUGS USED IN DIABETES		
Metformin	30-60	1500
	15-30	500
	<15	CI
Glibenclamide	<15	CI
Glimepiride	<15	CI
Acarbose	<30	50
Miglitol	<30	50
Sitagliptin	30-60	50
	<30	25
Vildagliptin	<60	50
Saxagliptin	<60	2.5
Exenatide	<30	NR
Liraglutide	<60	NR

D: Day; CI: contraindicated; NR: not recommended

^a National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. *Am. J. Kidney Dis.* 60, 850–886 (2012)

^b Guideline development group. Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min). *Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc.* 30 Suppl 2, ii1-142 (2015)